Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Two Treatment, Two Period, Two Sequence,Crossover, Bioequivalence Study of BH009 Against Winthrop (Docetaxel) Injection in Patients With Solid Tumors

NCT04889599 is registered in ClinicalTrials.gov with Zhuhai Beihai Biotech Co., Ltd as lead sponsor.

NCT NCT04889599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04889599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Two Treatment, Two Period, Two Sequence,Crossover, Bioequivalence Study of BH009 Against Winthrop (Docetaxel) Injection in Patients With Solid Tumors
Lead sponsor
Zhuhai Beihai Biotech Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2021
Completion date
September 24, 2021
Enrollment
46 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence, docetaxel, solid tumours